PURDUE PHARMA LP Company Profile

✉ Email this page to a colleague

PURDUE PHARMA LP has ten approved drugs.

There are sixty-five US patents protecting PURDUE PHARMA LP drugs.

There are four hundred and eighty-two patent family members on PURDUE PHARMA LP drugs in fifty-one countries and one supplementary protection certificate in one country.

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Purdue Pharma Lp	OXYCONTIN	oxycodone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022272-002	Apr 5, 2010		RX	Yes	No	8,894,988	⤷ Sign Up	Y			⤷ Sign Up
Purdue Pharma Lp	BUTRANS	buprenorphine	FILM, EXTENDED RELEASE;TRANSDERMAL	021306-005	Jun 30, 2014	AB	RX	Yes	No		⤷ Sign Up				⤷ Sign Up
Purdue Pharma Lp	OXYCONTIN	oxycodone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022272-003	Apr 5, 2010		RX	Yes	No	9,522,919	⤷ Sign Up	Y	Y		⤷ Sign Up
Purdue Pharma Lp	HYSINGLA ER	hydrocodone bitartrate	TABLET, EXTENDED RELEASE;ORAL	206627-007	Nov 20, 2014	AB	RX	Yes	No	9,095,614	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Purdue Pharma Lp	TARGINIQ	naloxone hydrochloride; oxycodone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205777-003	Jul 23, 2014	8,673,355	⤷ Sign Up
Purdue Pharma Lp	BUTRANS	buprenorphine	FILM, EXTENDED RELEASE;TRANSDERMAL	021306-002	Jun 30, 2010	9,642,850	⤷ Sign Up
Purdue Pharma Lp	TARGINIQ	naloxone hydrochloride; oxycodone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205777-002	Jul 23, 2014	8,846,091	⤷ Sign Up
Purdue Pharma Lp	BUTRANS	buprenorphine	FILM, EXTENDED RELEASE;TRANSDERMAL	021306-001	Jun 30, 2010	RE41408	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Transdermal System	15 mcg/hr	➤ Subscribe	2013-12-16
➤ Subscribe	Extended-release Tablets	30 mg, 40 mg, 80 mg, and 100 mg	➤ Subscribe	2015-05-08
➤ Subscribe	Extended-release Tablets	30 mg and 60 mg	➤ Subscribe	2007-01-03
➤ Subscribe	Transdermal System	5 mcg/hr, 10 mcg/hr, and 20 mcg/hr	➤ Subscribe	2013-06-06
➤ Subscribe	Extended-release Tablets	20 mg, 60 mg, and 120 mg	➤ Subscribe	2015-04-15
➤ Subscribe	Extended-release Tablets	15 mg	➤ Subscribe	2007-02-15

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration
Finland	U20070284	⤷ Sign Up
World Intellectual Property Organization (WIPO)	2014124464	⤷ Sign Up
Guatemala	200900023B	⤷ Sign Up
European Patent Office	3876938	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1685839	92292	Luxembourg	⤷ Sign Up	PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.